Article information
Abstract
An update on the conventional treatment of osteosarcoma, excluding secondary forms due to malignancies by other diseases, as well as the parosteal-juxtacortical forms. The overall survival is 73%, although the protocol is still open. The toxicity and changes established in the forms of administering the drugs to decrease the secondary effects in the short and long term are assessed.
Keywords:
Osteosarcoma
Bone tumour
Chemotherapy
Rescue surgery
Resumen
Se presenta una actualización del tratamiento del osteosarcoma convencional, con exclusión de las formas secundarias por malignización de otras patologías, así como las formas de osteosarcoma parostal-yuxtacortical. La supervivencia global es del 73%, aunque el protocolo sigue abierto y se evalúa la toxicidad y se plantean cambios en la forma de administrar las drogas para disminuir los efectos secundarios a corto y largo plazo.
Palabras clave:
Osteosarcoma
Tumor óseo
Quimioterapia
Cirugía de rescate
Full text is only aviable in PDF
References
[1.]
B. Carsi, M.G. Rock.
Primary osteosarcoma in adults.
Clin Orthoped Relat Res, 397 (2002), pp. 53-61
[2.]
M.W. Manoso, J.H. Healey, P.J. Boland, E.A. Athanasian, R.G. Maki, A.G. Huvos, et al.
De novo osteogenic sarcoma in patients older than forty: Benefit of multimodality therapy.
Clin Orthop Relat Res, 438 (2005), pp. 110-115
[3.]
S.Y. Lee, W.H. Cho, W.S. Song, J.H. Park.
Different radiological findings with the same pathologic diagnosis due to different age in primary osteosarcoma.
Acta Radiol, 47 (2006), pp. 841-844
[4.]
S.L. Wootton-Gorges.
MR imaging of primary bone tumors and tumor-like conditions in children.
Magn Reson Imaging Clin N Am, 17 (2009), pp. 469-487
[5.]
M. Kleis, H. Daldrup-Link, K. Matthay, R. Goldsby, Y. Lu, T. Schuster, et al.
Diagnostic value of PET/CT for the staging and restaging of pediatric tumors.
Eur J Nucl Med Mol Imaging, 36 (2009), pp. 23-36
[6.]
C.M. Costelloe, H.A. Macapinlac, J.E. Madewell, N.E. Fitzgerald, O.R. Mawlawi, E.M. Rohren, et al.
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma.
J Nucl Med, 50 (2009), pp. 340-347
[7.]
R. Wolf, W.F. Enneking.
The staging and surgery of musculoskeletal neoplasms.
Orthop Clin North Am, 27 (1996), pp. 473-481
[8.]
H.J. Mankin, T.A. Lange, S.S. Spanier.
The hazards of biopsy in patients with malignant primary bone and soft tissue tumors.
J Bone Joint Surg Am, 64 (1982), pp. 1121-1127
[9.]
O.S. Bruland, H. Høfødt, G. Saeter, S. Smeland, O. Fodstad.
Hematogenous micrometastases in osteosarcoma patients.
Clin Cancer Res, 11 (2005), pp. 4666-4673
[10.]
F. Eilber, A. Giuliano, J. Eckardt, K. Patterson, S. Moseley, J. Goodnight.
Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial.
J Clin Oncol, 5 (1987), pp. 21-26
[11.]
M.P. Link, A.M. Goorin, A.W. Miser, A.A. Green, C.B. Pratt, J.B. Belasco, et al.
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.
N Engl J Med, 314 (1986), pp. 1600-1606
[12.]
G. Rosen.
Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: A ten year experience.
Orthopedics, 8 (1985), pp. 659-664
[13.]
A.M. Goorin, D.J. Schwartzentruber, M. Devidas, M.C. Gebhardt, A.G. Ayala, M.B. Harris, et al.
Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: POG-8651.
J Clin Oncol, 21 (2003), pp. 1574-1580
[14.]
G. Rosen, B. Caparros, A.G. Huvos, C. Kosloff, A. Nirenberg, A. Cacavio, et al.
Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.
Cancer, 49 (1982), pp. 1221-1230
[15.]
P.A. Meyers, G. Heller, J. Healey, A. Huvos, J. Lane, R. Marcove, et al.
Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience.
J Clin Oncol, 10 (1992), pp. 5-15
[16.]
A.M. Goorin.
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial.
J Clin Oncol, 20 (2002), pp. 426-433
[17.]
J. Dubousset, G. Missenard, C.H. Califa.
Management of osteogenic sarcoma in children and adolescents.
Clin Orthop Rel Res, 373 (1991), pp. 51-61
[18.]
H.J. Mankin, S.H. Doppelt, T.R. Sullivan, W.W. Tomford.
Osteoarticular and intercalary allograft transplantation in the management of malignant tumors of bone.
Cancer, 50 (1982), pp. 613-630
[19.]
M.A. Simon.
Current concepts review: Limb salvage for osteosarcoma.
J Bone Joint Surg Am, 68-A (1986), pp. 1331-1339
Copyright © 2010. Sociedad Española de Cirugía Ortopédica y Traumatología (SECOT). All rights reserved
